Background {#Sec1}
==========

The diagnosis and management of presumed latent TB infection (LTBI) form an important strategy in the fight against TB. The identification of patients with LTBI at high risk of progression to active tuberculosis is deemed a research priority \[[@CR1]\]. The World Health Organization (WHO) currently recommends that testing and treatment for LTBI be performed on all HIV positive individuals. This recommendation is extended to populations deemed at increased risk of TB such as health care workers (HCWs) in low TB incidence settings only \[[@CR2]\]. However, there are considerable differences in screening guidelines between countries, with limited evidence to support choice and effectiveness of testing strategies \[[@CR3]\].

In South Africa, a high tuberculosis (TB) incidence country, the prevalence of LTBI in HCWs as measured by a positive tuberculin skin test (TST) ranges from 48 to 84% while HIV prevalence is \> 10% \[[@CR4]\]. Despite their high risk for active TB and increased exposure to TB in the workplace, screening for LTBI among HCWs is very limited in practice \[[@CR5]\].

Reasons include resource constraints as well as uncertainty about the performance of TST and interferon-gamma release assays (IGRAs). Stigma may also play a role -- as it is defined as devaluing a social trait or characteristic which can lead to discrimination of an individual or group. A diagnosis of tuberculosis through its association with poverty and HIV in this setting carries with it a considerable degree of stigma. A recent study of South African HCWs found stigma to be negatively associated with health seeking behavior such as screening for TB screening or presenting for Isoniazid prophylaxis \[[@CR6]\].

Despite low quality evidence, IGRAs have been proposed as acceptable alternatives to TST and have been incorporated into screening guidelines by WHO \[[@CR2], [@CR7]--[@CR9]\]. These assays react to early secreted antigenic target 6 (ESAT-6) and culture filtrate protein (CFP-10) encoded within the region of difference (RD1) of the *M tuberculosis* genome. Two IGRAs are available: QuantiFERON-TB Gold-In-Tube (QFT-GIT; format recently changed to QuantiFERON-TB Gold) (Cellestis Limited, Victoria, Australia) and TSPOT.TB (Oxford Immunotec, Oxford, UK). IGRAs have superior specificity and are less affected by cross reactivity with previous BCG vaccination than TST \[[@CR10], [@CR11]\]. There is marked discordance in test performance between TST and IGRAs. This phenomenon is partially accounted for by test properties but also appears to be modified by host, immunological and exposure factors. The utility of IGRAs in TB endemic settings has not been shown, and a clearer understanding of factors associated with discordance should result in a more informed approach to screening strategies. To address this knowledge gap we determined the occupational and non-occupational factors associated with TST/IGRA discordance in HCWs.

Methods {#Sec2}
=======

Participants were drawn from five primary healthcare facilities which provide TB diagnostic and treatment services, and two secondary level hospitals caring for patients with complicated, multi-drug-resistant or extremely drug- resistant TB. Five facilities were located in the Cape Town township of Khayelitsha, with a TB case notification rate of over 1600/100000, 70% of which represents with co-infection with HIV \[[@CR12]\].

All participants underwent administration of TST and venesection for QFT-GIT and T- SPOT.TB. TST was performed using 1 TU dose of PPD RT23 (Statens Serum Institut, Copenhagen, Denmark). A detailed methods section has previously been published \[[@CR13]\]. The value for a positive TST was a skin reaction measured as 10 mm in diameter. This relatively high cut-off was used to improve specificity- as there is near universal vaccination with BCG given at birth in South Africa. For those who were HIV-infected a value of 5 mm was considered a positive TST result to counteract a possible anergic effect due to immunosuppression.

Blood samples for the IGRA assays were drawn concurrently or within 3 days of administering TST. This interval has been shown to be sufficiently short to eliminate potential boosting \[[@CR14], [@CR15]\]. The QFT-GIT test was considered positive if the interferon- gamma response minus the nil antigen was ≥0.35 IU/ml. For TSPOT.TB, the number of IFN-λ spot forming T cells (SFC) per million peripheral blood mononuclear cells (PBMCs) was determined using an AIM ELISPOT reader and Oxford Immunotec software. A cut-off of six or more spots was treated as a positive result. To minimize inter-operator and inter-laboratory variability, all assays were done by one operator. Indeterminate results were treated as missing data and observations were not used in the agreement analysis.

Statistical analyses were performed using Stata version 11 (Stata Corp, College Station, Texas). Outcomes included agreement between the tests using the kappa statistic (κ), and factors associated with discordance. Agreement analyses was performed on baseline results and has been reported previously \[[@CR13]\].

Discordant pairs numbered six in total: TST + ve/IGRA-ve, TST- ve/IGRA+ve or IGRA+ve/ IGRA-ve. Factors associated with discordance at baseline were explored using a series of multinomial logistic regression models that compared discordant groups with a reference group displaying perfect agreement (negative and positive concordance). Discordance was evaluated between 2 different tests e.g. IGRA and TST or IGRA and IGRA. The association between each variable and two potential discordant test outcomes was then evaluated in one multinomial regression model. A multivariate analysis adjusting for all variables in the model was conducted. Significant covariates in the model were age, gender and HIV status. Variables included in the final model for all three tests were chosen on statistical significance (*p* \< 0.05) for any of the three tests in unadjusted analysis, and biological plausibility.

Results {#Sec3}
=======

Participants with TST and IGRA assay outcomes {#Sec4}
---------------------------------------------

The population eligible for participation were 764 HCWs. Based on voluntary participation, 505 HCWs were recruited, a 67% participation rate (Fig. [1](#Fig1){ref-type="fig"}). Owing to a higher rate of indeterminate results there were fewer valid test pairs available for comparison for TSPOT.TB (*n* = 450) than for QFT-GIT (*n* = 482).Fig. 1Study plan and flow diagram illustrating valid paired tests for the discordance analysis

Agreement between TST reactions and IGRA assays {#Sec5}
-----------------------------------------------

Agreement at baseline has previously been reported on for this study \[[@CR13]\]. There was only fair agreement between TST and the IGRAs, with κ = 0.28 \[95% confidence interval (CI) 0.20--0.36\] and κ = 0.25 (95% CI 0.18--0.33) for QFT-GIT and TSPOT.TB respectively.

Agreement between the two IGRA assays was moderate with κ = 0.65 (95% CI). Agreement analysis was performed between the IGRA assays and three different cut-offs for TST (≥5, ≥ 10 and ≥ 15 mm) without taking HIV status into consideration and was essentially unchanged across the different cut points.

Predictors of discordant test responses {#Sec6}
---------------------------------------

Table [1](#Tab1){ref-type="table"} presents the results of the multinomial models used to estimate the relative odds of discordant results between QuantiFERON-TB Gold-in-tube and tuberculin skin test. The reference category for all models includes pairs displaying perfect agreement, with both tests giving the same result, either positive or negative.Table 1Results of multinomial regression models for discordant QuantiFERON-TB Gold-in-tube and tuberculin skin test at baselinePositive TST and negative QFT-GIT test resultNegative TST and positive QFT-GIT test resultRisk FactorOR (95% CI) *N* = 112AdjustedOR (95% CI) *N* = 24AdjustedOlder age, per each additional year0.99 (0.70--1.01)1.00 (0.97--1.02)1.01 (0.98--1.05)1.08 (1.03--1.13) \*\*Male gender0.93 (0.57--1.52)0.75 (0.44--1.28)1.15 (0.46--2.87)1.07 (0.38--3.04)BCG Vaccination scar1.28 (0.74--2.21)1.27 (0.69--2.31)1.06 (0.39--2.92)0.83 (0.25--2.79)HIV Positive / reported as positive1.12 (0.55--2.25)1.07 (0.47--2.42)1.97 (0.63--6.16)2.38 (0.58--9.71)Previous TB Treatment1.03 (0.55--1.94)1.16 (0.57--2.36)1.34 (0.44--4.09)0.73 (0.16--3.27)Symptom screen positive0.67 (0.40--1.13)0.59 (0.33--1.04)1.56 (0.66--3.69)1.15 (0.42--3.16)Years in healthcare0.99 (0.97--1.01)0.98 (0.95--1.01)0.94 (0.89--0.99) \*0.90 (0.84--0.96)\*\*Home care of TB0.73 (0.31--1.71)0.70 (0.28--1.72)0.99 (0.22--4.44)0.30 (0.04--2.59)Daily contact with TB patients0.78 (0.39--1.5)0.85 (0.40--1.80)1.12 (0.25--4.99)2.20 (0.27--17.76)*OR* odds ratio, *CI* confidence interval\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001

Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} presents analogous results for the analysis of discordant results between TSPOT.TB and tuberculin skin test and between QFT-GIT and TSPOT.TB, respectively.Table 2Results of multinomial regression models for discordant TSPOT.TB and tuberculin skin test at baselineRisk FactorPositive TST and negative\
TSPOT.TB test resultNegative TST and positive\
TSPOT.TB test resultOR (95% CI) *N* = 126AdjustedOR (95% CI) *N* = 20AdjustedOlder age, per each additional year0.97 (0.95--0.99) \*\*0.97 (0.94--0.99)\*1.00 (0.96--1.04)1.07 (1.01--1.13)\*Male gender0.93 (0.58--1.50)0.72 (0.43--1.21)1.22 (0.45--3.29)1.46 (0.45--4.75)BCG Vaccination scar1.42 (0.82--2.46)1.92 (1.02--3.63) \*1.07 (0.34--3.32)1.04 (0.26--4.17)HIV Positive/reported as positive1.03 (0.50--2.11)0.88 (0.37--2.05)4.72 (1.64--13.59) \*\*4.44 (1.14--17.27)\*Previous TB Treatment0.88 (0.46--1.68)1.02 (0.48--2.17)3.00 (1.09--8.28)\*1.33 (0.35--5.10)Symptom screen positive1.05 (0.65--1.68)1.03 (0.60--1.75)2.95 (1.18--7.35) \*1.94 (0.64--5.86)Years in healthcare0.98 (0.96--1.0)1.00 (0.97--1.03)CI (0.88 - 0.99)\*0.92 (0.85--0.99)\*Home-care0.32 (0.11--0.94) \*0.32 (0.10--0.95) \*1.74 (0.48--6.30)0.63 (0.11--3.56)Daily contact with TB patient0.88 (0.45--1.71)0.94 (0.45--1.98)2.08 (0.27--16.09)NC*OR* odds ratio, *CI* confidence interval\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001Table 3Results of multinomial regression models for discordant QFT-GIT and TSPOT.TB at baselinePositive QFT-GIT and negative\
TSPOT.TB test resultNegative QFT-GIT and positive\
TSPOT.TB test resultRisk FactorOR (95% CI) *N* = 47AdjustedOR (95% CI) *N* = 29AdjustedOlder age, per each additional year95% CI ; 0.94 - 0.99) \*0.99 (0.95--1.03)0.97 (0.92--1.01)1.03 (0.99--1.08)Male gender0.98 (0.50--1.97)0.98 (0.47--2.05)1.09 (0.47--2.55)1.54 (0.57--4.13)BCG Vaccination scar0.66 (0.33--1.33)0.88 (0.37--2.01)0.54 (0.22--1.15)0.48 (0.19--1.23)HIV Positive/reported as positive1.18 (0.44--3.18)1.66 (0.53--5.24)5.11 (2.11--12.33) \*\*\*5.72 (1.95--16.78)\*\*Previous TB Treatment0.29 (0.07--1.22)0.24 (0.05--1.17)1.34 (0.49--3.67)0.74 (0.23--2.36)Symptom screen positive1.35 (0.70--2.59)1.48 (0.71--3.08)1.09 (0.47--2.55)0.78 (0.29--2.11)Years in healthcare0.97 (0.93--1.00)0.97 (0.93--1.02)0.97 (0.93--1.01)0.95 (0.90--1.01)Home-care0.26 (0.03--1.94)0.24 (0.03--1.85)3.10 (1.17--8.21) \*2.42 (0.77--7.56)Daily contact with TB patient0.59 (0.24--1.40)0.71 (0.27--1.87)0.64 (0.21--1.94)1.04 (0.27--4.00)*OR* odds ratio, *CI* confidence interval\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001

### BCG {#Sec7}

A TST + ve/IGRA-ve discordant test response was more likely in those with a BCG vaccination scar and significantly so for TST + ve/TSPOT.TB-ve. BCG scar positive Individuals were less likely to have QFT-ve/TSPOT.TB + ve discordance.

### Length of service {#Sec8}

HCWs with more years in healthcare employment were less likely to have a discordant test (TST-ve/IGRA+ve) outcome; in other words, TST/IGRA discordance declined with duration of employment.

### HIV status {#Sec9}

HIV infected individuals were more likely to test TSPOT.TB + ve/ TST-ve and TSPOT.B + ve /QFT-GIT-ve, relative to HIV negative HCWs.

### Home-based care {#Sec10}

HCWs engaged in home care were less likely to have a discordant test (TST + ve/ TSPOT.TB-ve) response.

Discussion {#Sec11}
==========

This study evaluated factors associated with discordant test responses for presumed latent TB infection in healthcare workers in a high TB and HIV prevalence setting. It found the following factors significantly associated with an increased odds of discordance: HIV infection, long exposure in healthcare environments and BCG vaccination. The finding of a markedly increased odds of a discordant test response in HIV-infected HCWs (OR = 4.44) for TSPOT.TB + ve/TST-ve and (OR = 5.72) for TSPOT.TB + ve/QFT- GIT-ve suggests that TSPOT.TB test performance is relatively unimpaired by HIV infection in this population and is therefore a potentially more sensitive assay than TST for detecting LTBI in HIV-infected HCWs \[[@CR16], [@CR17]\]. A meta- analysis by Cattamanchi et al. did not show IGRAs as a class to be consistently more sensitive than TST in HIV-infected individuals but did conclude that the TSPOT.TB assay exhibited higher sensitivity and was less affected by immunosuppression, than either TST or QFT-GIT \[[@CR18]\]. A subsequent review by Overton et al. similarly concluded that the rate of reactivity of both IGRAs and TST was affected by the level of HIV-associated CD4 T-cell deficiency and that all assays appeared to be affected by the degree of CD4 T-cell depletion, with the possible exception of the TSPOT.TB assay \[[@CR19], [@CR20]\]. It is noted however that studies included in the systematic reviews were heterogeneous, few performed head to head comparisons between TST and IGRAs, and there were few studies specifically evaluating the performance of TSPOT. TB. As suggested by the epidemiological finding in this study, the performance of TST and QFT- GIT appears to be more susceptible to CD4 T cell depletion, manifesting as anergic TST responses and low-mitogen QFT-GIT responses with CD4 count acting as an effect modifier. Overton et al. further conclude that the likelihood of a positive reaction in the TST or ELISA-based IGRA at low CD4 levels is negligible.

Alternative explanations for the IGRA-TST and IGRA-IGRA discordance may include the test format (ELISPOT is a cell-based readout and therefore inherently more sensitive than ELISA), the use of different test-specific antigen formulations that may differentially turn on regulatory (inhibitory) pathways, host factors, strain type, or likely a combination of these factors \[[@CR21], [@CR22]\]. Emerging research suggests that different *M. tb* strains differentially regulate host IFN-gamma responses in HIV negative individuals and that these differences may be a result of genetic differences in the ESX-1 region. This could in part explain some of the differences seen in test responses to different IGRA assays \[[@CR23]\].

However in the absence of diagnostic certainty and a gold standard for LTBI, it remains difficult to conclusively assume increased sensitivity of IGRAs compared to TST.

The significantly decreased odds of a TSPOT.TB-ve/ TST + ve discordance in home- carers (after controlling for HIV) is of relevance. Community health workers comprise a large and growing population of health workers and form the backbone of the TB control programmes in their role as treatment and adherence supporters through home visits, often in impoverished settings including informal housing settlements. Drawn from the same communities as their clients, their risk for both TB and HIV has been shown to be greater than that of the general population \[[@CR24]\].

The decrease in TST-ve / IGRA+ve discordance with duration of employment is not unexpected as increased risk of LTBI has been associated with increased length of employment in several studies for both IGRAs and TST \[[@CR25], [@CR26]\]. The underlying mechanism of this duration effect may be one in which IGRA is more likely than TST to detect recent infection (involving CD4 T-cells that have encountered antigens recently in vivo), whereas TST detects cumulative exposure to M. tuberculosis over time (involving CD4 T- cells of the memory phenotype) \[[@CR27], [@CR28]\]. In this study BCG vaccination (as assessed by presence of a vaccination scar) was positively associated only with a TST + ve/TSPOT.TB- ve outcome and not with TST + ve/QFT-ve discordance, suggesting an effect on TST test response. This is similar to a large study in Chinese healthcare workers, which showed higher rates of LTBI as measured by TST in those with vaccination scars \[[@CR29]\]. However, not all studies have found an association between discordance and BCG vaccination given at birth only, with at least two reviews reporting that the influence of BCG is relatively limited in the adult population 10 years or more after BCG vaccination \[[@CR22], [@CR30]\].

There are several limitations to this study. Voluntary participation and limited participation by clinical staff due to high workload may have resulted in selection bias. The high rate of indeterminate results for TSPOT.TB also resulted in a smaller sample being available for analysis of discordance for this assay. The lack of data on extent of immunosuppression as reflected by CD4 is another limitation. This information could have enhanced our understanding of the spectrum of IGRA test response in those who are HIV infected. The use of standardized cut-offs to denote test positivity is another factor that may influence some of the associations shown. The widespread use of IGRAs in serial testing programmes have highlighted the variability of these assays and the need for a more cautious approach to interpretation of test positivity for values close to the cut-off \[[@CR31]\]. An exploration of different TST and IGRA cut points may inform a more nuanced understanding of factors associated with discordance. Lastly the lack of a gold standard to confirm LTBI diagnosis makes it difficult to compare test performance and arrive at conclusive answers in this regard.

Conclusion {#Sec12}
==========

In this population BCG vaccination is associated with discordance suggesting an enduring effect for BCG given at birth and likely impact on TST test specificity. The markedly discordant test response in HIV infected HCWs found in this study is compatible with potentially greater sensitivity or reactivity of TSPOT.TB in immunocompromised individuals. Whilst it is known that both IGRAs and TST are only modestly predictive of subsequent TB risk, LTBI diagnosis and treatment remains one of the interventions recommended by the World Health Organization (WHO) to end the TB epidemic worldwide \[[@CR32], [@CR33]\]. In high-incidence countries it is imperative that such screening selectively and accurately targets those at sufficiently high risk of progressing to disease.

A potentially increased test sensitivity of TSPOT.TB in a setting of a high prevalence of HIV would allow for more targeted IPT for those at greatest risk of progression to disease. This may enhance its potential utility in a TB and HIV endemic setting where at least 10% of HCWs are HIV-infected and face a six-fold higher risk of contracting TB, as has been shown to be the case among HCWs working in South African hospitals \[[@CR34]\].
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